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Abstract
Checkpoint kinase 2 (Chk2) is a major regulator of DNA damage response and can induce alternative cellular responses: cell
cycle arrest and DNA repair or programmed cell death. Here, we report the identification of a new role of Chk2 in
transcriptional regulation that also contributes to modulating the balance between survival and apoptosis following DNA
damage. We found that Chk2 interacts with members of the NCoR/SMRT transcriptional co-regulator complexes and serves
as a functional component of the repressor complex, being required for recruitment of SMRT on the promoter of pro-
apoptotic genes upon DNA damage. Thus, the co-repressor SMRT exerts a critical protective action against genotoxic stress-
induced caspase activation, repressing a functionally important cohort of pro-apoptotic genes. Amongst them, SMRT is
responsible for basal repression of Wip1, a phosphatase that de-phosphorylates and inactivates Chk2, thus affecting a
feedback loop responsible for licensing the correct timing of Chk2 activation and the proper execution of the DNA repair
process.
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Introduction
The induction of DNA damage by environmental carcinogens
induces a very complex response aimed at repairing the alterations
in the DNA structure and sequence [1,2]. The detection of base
modifications or strand breaks by sensor proteins induces the
activation of a checkpoint response that allows the cell to block
proliferation and to repair DNA [3–5]. If the damage is too
extensive to be reversed, checkpoint proteins induce a switch from
repair to programmed cell death, thereby preventing the
transmission of mutations to the next cellular generations [6].
Caspase activation is a central event in the induction of apoptosis
after DNA damage as well as other stimuli [6]. The mechanisms
by which a cell discriminates between reparable damage and lethal
genotoxic stress leading to caspase activation and apoptosis are not
well understood.
Checkpoint kinase 2 (Chk2) is a central DNA damage
checkpoint regulator [7,8], responding mostly to stimuli that cause
double strand breaks, such as ionizing radiation or topoisomerase
II inhibitors such as doxorubicin. The kinase ATM is involved in
sensing the damage and initiating the checkpoint response [9].
Among other substrates, ATM phosphorylates Chk2 on threonine
68 [10,11], inducing dimerization of Chk2 and auto-phosphory-
lation of multiple sites, leading to full activation [12–15]. Chk2
activation results in cell cycle arrest [16] and activation of the
DNA repair process [17,18]. Finally, if the damage is too extensive
to be repaired, Chk2 is able to induce apoptosis, through
phosphorylation of the pro-apoptotic transcription factors p53
[19,20] and E2F1 [21].
It has been shown that the ATM-Chk2-p53 system is activated
with an oscillatory pattern, as a consequence of the equilibrium
between activating stimulus (DNA damage) and a double feedback
system activated by p53 and including Mdm2, which induces p53
degradation [22], and Wip1, a protein phosphatase that dephos-
phorylates both ATM and Chk2 [23]. The oscillations are
considered a mechanism to check on the progress of the DNA
damage and shut down the checkpoint response if the repair has
been successful [24]. It has also been proposed that the oscillatory
activation of p53 provides a means to fine-tune the cellular
response and produce different outcomes according to the severity
of the DNA damage [25].
Besides p53, other transcription factors play different roles in
modulating the apoptotic response to DNA damage. Among these,
NFkB and AP1 have a fundamental function. NFkB shows
preeminent pro-survival actions in non-lymphoid tissues [26–29];
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however, it has been shown that DNA damaging stimuli such as
UV-C and doxorubicin/daunorubicin induce a switch of NFkB
action from activator to repressor on the anti-apoptotic genes X-
IAP, Bcl-X(L) and survivin, thus contributing to the induction of
programmed cell death [30].
AP1 has been associated with regulation of apoptosis in
response to a wide variety of stimuli, such as growth factor
deprivation and environmental stresses, including DNA damage
[31,32]. The pro-apoptotic action is mediated by the transcrip-
tional activation of FasL, that triggers the extrinsic apoptotic
pathway [33], as well as Bim [34]. AP1-mediated repression also
plays an important role in regulating the apoptotic switch: proteins
of the AP-1 family are able to repress pro-apoptotic genes such as
p53 [35,36] and Fas [37]; therefore, the final outcome depends on
the balance between gene activation and repression, and is highly
influenced by several considerations including cell type, conditions
of growth, and the presence of growth factors [38]. It is generally
accepted that DNA damage activates initially both pro-apoptotic
and anti-apoptotic pathways, each one subjected to subtle and
complex regulation by different stimuli and transcription factors,
and that the overall balance between genes promoting survival and
genes inducing death signals dictates the cellular outcome [31].
Transcriptional co-repressors, recruited by transcription factors
bound on DNA regulatory elements, act as a platform for further
recruitment of repressive proteins including histone deacetylases or
methyltransferases, which locally modify the structure of chroma-
tin in a way that restricts access to activator complexes and RNA
polymerases [39]. The core NCoR/SMRT co-repressor complex-
es contain the histone deacetylase HDAC3 [40], the exchange
factors TBL1 and TBLR1 [41–43], and the G-protein pathway
suppressor, GPS2 [44]. The NCoR/SMRT complexes are
required for basal repression of genes by unliganded nuclear
receptors, such as thyroid hormone receptor (TR) and retinoic
acid receptor (RAR) [43], or for active repression mediated by
ligand-bound receptors, such as tamoxifen-bound estrogen recep-
tor [45]. NCoR/SMRT have also been associated with repression
by a number of other transcription factors, including the regulators
of apoptosis NFkB [46] and AP1 [47].
Although sharing significant sequence and structure homology
and the interaction with members of the respective co-repressor
complexes [43,48,49], NCoR and SMRT have been shown to
play distinct and specific roles in differentiation and development
[50–52], and to be subjected to different regulatory pathways
[51,53,54].
Here we report the finding that, upon DNA damage, Chk2 is
required to specifically recruit the co-repressor SMRT to repress
pro-apoptotic genes, including AP1 and NFkB targets, thus
keeping the apoptotic response on hold, while the cells repair
the damage. In particular, SMRT-dependent repression of the
protein phosphatase Wip1, a major regulator of checkpoint
response that de-phosphorylates Chk2, ATM, p53 and p38 [55],
is fundamental for caspase activation after DNA damage by
modulating the oscillatory frequency of Chk2 activation.
Results
Chk2 interacts with SMRT and regulates different
transcription factors, acting as a repressor
To gain insight into the role of the checkpoint kinase Chk2 in
the regulation of the apoptotic switch after DNA damage
[19,56,57], we first sought to identify the protein complex
associated with Chk2. To this end the protein interaction domain
(FHA domain) of human Chk2 was expressed in bacteria and the
purified protein incubated with HeLa cell extract. This approach
identified, amongst others, TBLR1, a component of the NCoR/
SMRT co-repressor complexes, as a Chk2 interacting protein
(Figure S1A–B). To confirm the interaction, flag-tagged full-length
human Chk2 was expressed both in HeLa (data not shown) and
U2OS cells and anti-Flag antibody was used to immunoprecipitate
associated proteins, followed by Western blot analysis with
antibodies specific for members of the NCoR/SMRT complexes
(NCoR, SMRT, TBL1, TBLR1). This approach confirmed the
interaction of Chk2 with SMRT, TBL1 and TBLR1, but not with
NCoR (Figure S1C). When the same experiment was performed
using flag-tagged Chk1 for comparison, no interaction was
detected.
To initially explore if Chk2 had an effect on transcription, an
array of luciferase expression vectors containing binding sites for
different transcription factors (AP1, NFkB and RAR), which use
NCoR/SMRT as co-repressors, were used to perform standard
reporter assays. Knock-down of Chk2 in U2OS cells potentiated
the transcriptional response to AP1 and RAR-driven reporters
(Figure S1D), suggesting a repressive function for Chk2.
SMRT, but not NCoR, significantly affects DNA damage-
induced transcription
Because Chk2 is a major regulator of DNA damage checkpoint
response, we sought to determine potential roles of the NCoR/
SMRT co-repressor complex in the transcriptional response to
DNA damage. Osteosarcoma cells U2OS were chosen because
they have a functional p53 and represent a good model for
studying DNA damage checkpoint. A time-course experiment in
U2OS cells showed that the genotoxic drug cisplatin (CDDP) at
the concentration of 100 mM caused phosphorylation of Chk2 on
T68 starting at 4 h and reaching a peak at 6 h (Figure S2). The
peak of Chk2 activation was followed by caspase activation
reaching a plateau at 8 h (Figure S2) Caspase activation was
evaluated through an antibody that specifically recognizes the
PARP fragment after the cleavage by caspase 3 on Asp214, while
not interacting with the full-length protein or with other PARP
degradation fragments (Figure S2).
To study the role of NCoR and SMRT in CDDP-induced gene
transcription, U2OS cells were transfected with siRNAs against
SMRT or NCoR, and 48 hours later treated with 100 mM CDDP
for 6 h to induce damage and activate Chk2. RNA was extracted,
labeled and hybridized on Illumina BeadChip microarrays. To
control the efficiency of knock-down, RT-qPCR was performed
with primers specific for NCoR or SMRT. As shown in Figure 1A,
the siRNAs against NCoR and SMRT caused a reduction in the
respective mRNA levels of 71% and 65%. The microarray
profiling showed that treatment with CDDP induced a massive
wave of gene repression, with negatively-regulated genes (1074)
being twice as frequent as positively-regulated (507) ones (Figure 1B
and Table S1), suggesting that transcriptional repression is an
important aspect of the response to CDDP-induced DNA damage.
Gene Ontology analysis of CDDP-regulated genes showed
enrichment, among the most significant biological processes, of
negative regulation of transcription, cell cycle, apoptosis, and cell
death (Table 1). The reduction of NCoR levels did not
significantly affect the CDDP-induced transcriptional program,
with only 36 genes being significantly regulated by CDDP
differently in the NCoR knock-down compared to the scramble
siRNA-transfected cells (FDR$0.2, Table S2). Conversely, knock-
down of SMRT resulted in significant changes in the transcrip-
tional program triggered by CDDP (Figure 1C and Table S3).
Among the CDDP-repressed genes, 186 (16%) were no longer
repressed or were significantly less repressed with SMRT knocked-
down (Figure 1C, upper panel and Class 1 in Table S3), while 99
SMRT Represses Pro-Apoptotic Genes
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genes (9%) where repressed more intensely in the absence of
SMRT. Among the CDDP-activated genes, 37 (7.8%) were
activated more intensely in the SMRT knock-down cells (Figure 1C,
lower panel), indicating that this co-repressor limits the activation
of these genes after CDDP treatment, while 94 (19.9%) were not
activated or activated less intensely when SMRT was knocked
down. Moreover, 17% of the genes activated by treatment with
CDDP were also activated by SMRT knock-down in the absence
of treatment (Class 2 in Table S3), suggesting a basal repression by
SMRT, which is removed by treatment with CDDP. Figure 1D
reports a heat map of a selected group of genes regulated by
CDDP differently in the SMRT knock-down compared to the
NCoR knock-down, showing how the profile in the NCoR siRNA
resembled the profile in the scramble siRNA-transfected cells,
while the SMRT siRNA stood out for both activation and
repression of genes. Interestingly, in the group of genes that were
differentially regulated by CDDP in the cells where SMRT was
knocked down compared to scramble siRNA-transfected cells,
some of the most enriched GO terms were cell death and
apoptosis, along with protein amino acid phosphorylation
(Table 2).
SMRT protects against apoptosis through repression of
pro-apoptotic genes
Because apoptosis was among the most enriched Gene
Ontology (GO) terms in SMRT-dependent genes, we selected a
group of pro-apoptotic genes regulated by CDDP (FOS, PPM1D,
SMAD7, SRPK2, BCL2L11, MAX), and performed RT-qPCR after
transfection of the cells with siRNA against SMRT and subsequent
treatment with CDDP. As shown in Figure 2A, SMRT limited
CDDP-dependent activation of FOS and PPM1D and exhibited a
repressive function on SMAD7, SRPK2, BCL2L11 and MAX, as
their inhibition by CDDP was lost in the cells transfected with
SMRT siRNA. Because AP1 is a transcription factor implicated in
induction of apoptosis, itself utilizing the NCoR/SMRT complex
for repression of target genes, the regulation of c-FOS, a major
component of the AP1 family, was selected for further investiga-
tion. Chromatin immunoprecipitation of SMRT following CDDP
treatment revealed increased recruitment of SMRT on the c-FOS
promoter after DNA damage (Figure 2B), suggesting direct
regulation of c-FOS by SMRT. Knock-down of Chk2 was able to
abrogate the occupancy of SMRT on the c-FOS promoter,
supporting the requirement for Chk2 in DNA damage-dependent
co-repressor recruitment (Figure 2C).
In order to investigate the biological consequences of the Chk2-
SMRT regulatory events, U2OS and 293 cells were transfected
with siRNAs against Chk2 or SMRT, followed by treatment with
toxic doses of CDDP and Western blot analysis of the caspase 3-
dependent cleavage of PARP1. As shown in Figure 3A, while the
siRNAs against Chk2 had little effect on the activation of caspase 3,
knock-down of SMRT increased PARP cleavage in CDDP-treated
cells. The knock-down of SMRT caused a very slight increase in
PARP cleavage also in non-treated cells, only visible after very
long exposure (Figure 3B). To confirm activation of caspase 3 by
SMRT siRNA, a Western blot was performed on U2OS protein
extracts with an antibody which specifically recognized the 17-kDa
and 19-kDa cleavage products of caspase 3, showing increased
caspase 3 cleavage when SMRT was knocked-down (Figure 3C).
This effect was not detected in cells transfected with the same
siRNAs, but treated with TNF-a in combination with cyclohex-
imide, which has been shown to activate the extrinsic apoptotic
pathway by the TNF receptor [58] (Figure 3D–E).
Figure 1. SMRT, but not NCoR, affects CDDP-induced tran-
scriptional program. A) U2OS cells were transfected with scramble
siRNA or with siRNAs for NCoR or SMRT, and then treated with 100 mM
CDDP for 6 h, followed by RNA extraction and RT-qPCR with primers
specific for NCoR (left panel) or SMRT (right panel). Results from three
independent experiments, each with three technical replicates, were
analyzed by the DDCt method, using 18S as a normalizer. (Student’s T-
test; one star: p-value#0.05, two stars: p-value#0.01, three stars: p-
value#0.001). B–D) RNAs from two of the biological replicates
described in A were subjected to labeling and hybridization on Illumina
BeadChip arrays. B) The histogram indicates the number of genes that
SMRT Represses Pro-Apoptotic Genes
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SMRT represses the phosphatase Wip1, influencing the
dynamics of Chk2 activation
Interestingly, SMRT was required for CDDP-induced repres-
sion of the Wip1 phosphatase (PPM1D gene, Figure 2A), a major
down-regulator of the Chk2 pathway, as well as of other
phosphorylated proteins such as p53 and p38 [55]. To confirm
the repressive action of SMRT on PPM1D, U2OS cells were
transfected with siRNA against SMRT and treated with another
genotoxic drug, doxorubicin, which inhibits topoisomerase II and
causes double strand breaks. As expected, Wip1 protein levels
were augmented by doxorubicin treatment and increased by
siRNA against SMRT, even in the absence of DNA damage,
indicating basal repression of PPM1D by SMRT (Figure 4A).
We next investigated the role of PPM1D repression in the initial
caspase activation induced by SMRT knock-down in the presence
of DNA damage. We first treated the cells with doxorubicin for
different time points, and detected cleavage of PARP starting
between 5 h and 6 h of treatment (Figure 4B). While knock-down
of SMRT caused an increase in doxorubicin-induced caspase 3
activation, co-treatment with a chemical inhibitor of Wip1
attenuated this phenotype (Figure 4C). Consistently, co-transfec-
tion of siRNA against PPM1D reduced caspase activation when
compared to actions of SMRT siRNA alone (Figure 4D, compare
lane 4 and 2).
Wip1 has many substrates, all involved in the regulation of
apoptosis in response to DNA damage or cellular stresses. To
determine whether Chk2 is required for the activation of caspase
that occurs when SMRT is down-regulated, we co-transfected
U2OS cells with siRNAs for SMRT and Chk2. Indeed, co-
transfection with Chk2 siRNA attenuated the caspase activation
caused by SMRT knock-down, after treatment with doxorubicin
(Figure 4D, compare lanes 6 and 2).
are either activated or repressed by CDDP, using a log2 fold change cut-
off of 0.585. C) The two histograms report the number of genes whose
regulation by CDDP is affected by SMRT knock-down, grouped by CDDP
repression (upper panel) or activation (lower panel). D) Genes regulated
by CDDP differently in the SMRT knock-down compared to the NCoR
knock-down. The criteria for selection of SMRT-specific genes were the
following: false discovery rate $0.2; log2 fold change (CDDP/vehicle) in
scramble siRNA cells $|0.32|; difference between log2 fold changes in
the SMRT knock-down and the scramble siRNA [(siSMRT+CDDP/
siSMRT+vehicle) – (siCtl+CDDP/siCtl+vehicle)] $0.32; difference be-
tween log2 fold changes in the SMRT knock-down and the NCoR knock-
down [(siSMRT+CDDP/siSMRT+vehicle) – (siNCoR+CDDP/siNCoR+
vehicle)] $0.32. Genes were grouped with the ‘‘Cluster’’ software
(using the ‘‘Average linkage clustering’’ function) and the heat maps
were created with the ‘‘TreeView’’ software.
doi:10.1371/journal.pone.0059986.g001
Table 1. Most enriched Gene Ontology (GO) terms in CDDP-regulated genes.
GO ID Biological Process p
45941 positive regulation of transcription 2.77E-14
6468 protein amino acid phosphorylation 5.51E-13
122 negative regulation of transcription from RNA
polymerase II promoter
4.28E-12
30154 cell differentiation 5.98E-12
51093 negative regulation of developmental process 1.65E-11
7049 cell cycle 3.51E-11
7167 enzyme linked receptor protein signaling pathway 3.65E-11
42127 regulation of cell proliferation 5.74E-11
1568 blood vessel development 1.07E-09
43066 negative regulation of apoptosis 1.31E-09
6915 apoptosis 3.47E-09
51094 positive regulation of developmental process 3.67E-09
8219 cell death 3.71E-09
doi:10.1371/journal.pone.0059986.t001
Table 2. Most enriched Gene Ontology (GO) terms in genes
whose regulation by CDDP is affected by SMRT.
GO ID Biological Process p
6468 protein amino acid phosphorylation 7.33E-13
8219 cell death 8.35E-13
7049 cell cycle 5.34E-12
6915 apoptosis 7.86E-12
12501 programmed cell death 1.37E-11
33554 cellular response to stress 3.71E-10
10558 negative regulation of macromolecule
biosynthetic process
1.00E-09
6357 regulation of transcription from RNA
polymerase II promoter
1.13E-09
10629 negative regulation of gene expression 1.43E-09
9966 regulation of signal transduction 1.62E-09
51094 positive regulation of developmental process 1.79E-09
16481 negative regulation of transcription 1.92E-09
8283 cell proliferation 2.41E-09




10926 anatomical structure formation 5.46E-09
44085 cellular component biogenesis 5.86E-09
doi:10.1371/journal.pone.0059986.t002
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Because the Wip1-dependent feedback has been reported to
cause oscillatory behavior in Chk2 activation [24,59], and because
in genetic oscillators the intensity of the feedback loop dictates the
oscillatory behavior of the system [60–62], we sought to examine
the possibility that the SMRT-dependent repression ofWip1might
be responsible for influencing the dynamics of Chk2 activation
after DNA damage. U2OS cells were treated with doxorubicin at
109 intervals for 2 hours, comparing cells transfected with
scramble siRNA or siRNA against SMRT. In control conditions,
an oscillatory pattern of Chk2 phosphorylation was observed, with
two discrete peaks at 409 and 809. SiRNA against SMRT altered
this pattern, resulting in only one, more persistent phospho-Chk2
peak (Figure 4E). Interestingly, when the cells transfected with the
Figure 2. SMRT represses a group of pro-apoptotic genes. A)
RT-qPCR was performed on RNA extracted from U2OS cells after
treatment for 6 h with 100 mM CDDP, with or without siRNA against
SMRT. Results from three independent experiments, each with three
technical replicates, were analyzed by the DDCt method, using 18S as a
normalizer. B) Chromatin immunoprecipitation with an antibody
specific for SMRT after treatment of 293 cells with 100 mM CDDP for
2 h. The qPCR was performed on the immunoprecipitated DNA, and
percentage of the input was calculated by comparing the sample Ct
with a curve made of four serial 1/5 dilutions of 1% input. The results
are the average of three independent experiments, each one with three
technical replicates. C) Same as in B, but with transfection of either
scramble siRNA or siRNA against Chk2 and qPCR with specific primers
for FOS promoter (left panel) or IL8 exon 4 (right panel). The results are
the average of three independent experiments, each one with three
technical replicates. (Student’s T-test performed for all experiments in
the figure; one star: p-value#0.05, two stars: p-value#0.01, three stars:
p-value#0.001).
doi:10.1371/journal.pone.0059986.g002
Figure 3. SMRT has a protective action against DNA damage-
induced caspase activation. A–C) 293 and U2OS cells were
transfected with the indicated siRNAs and treated with either DMSO
or 100 mM CDDP for 8 h, followed by Western blot analysis on whole
cell extracts with the indicated antibodies. D–E) U2OS cells were
transfected with the indicated siRNAs and treated with either 100 mM
CDDP or 20 ng/ml TNF-a + 5 mg/ml cycloheximide for 6 h. All shown
data is representative of at least three independent experiments.
GAPDH is used as a loading control.
doi:10.1371/journal.pone.0059986.g003
SMRT Represses Pro-Apoptotic Genes
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Figure 4. Wip1 and Chk2 are required for activation of caspase by SMRT knock-down after DNA damage. A) U2OS cells were
transfected with scramble siRNA (Ctl) or siRNA against SMRT and then treated with 5 mM doxorubicin for the indicated time points, followed by
protein extraction and Western blot with the indicated antibodies. B) U2OS cells were treated with 5 mM doxorubicin for the indicated time points
and protein extracts were used for Western blot. C) U2OS cells were transfected either with scramble siRNA or with siRNA against SMRT and then
treated for 6 h with 5 mM doxorubicin with or without co-treatment with 50 mM PPM1D inhibitor, and the protein extracts were used for Western blot
with antibodies specific for cleaved PARP1 and tubulin. D) U2OS cells were transfected with the indicated siRNAs and then treated with for 6 h with
5 mM doxorubicin; the protein extracts were used for Western blot with antibodies specific for cleaved PARP1 and tubulin. E) U2OS cells were treated
with 5 mM doxorubicin at 109 intervals for 2 h, and protein extracts were analyzed by Western blot with phospho-Chk2 (T68) or tubulin antibodies,
both in control cells and in the SMRT knock-down. F) Cells were transfected with siRNA against SMRT and treated with doxorubicin for the indicated
time points, with (lower panel) or without (upper panel) additional treatment with PPM1D inhibitor. All shown data is representative of at least three
independent experiments.
doi:10.1371/journal.pone.0059986.g004
SMRT Represses Pro-Apoptotic Genes
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SMRT siRNA were also treated with a Wip1 inhibitor, the single
peak of Chk2 activation (Figure 4F, upper panel) was replaced by
two peaks of activation after doxorubicin treatment, one at 409–
509 and one at 709 (Figure 4F, lower panel). Even if the peaks are
not perfectly overlapping with the original oscillation observed in
the wild type cells, this result suggests that the lack of inhibition of
Wip1 might play a role in the altered dynamics observed in the
SMRT knock-down.
SMRT is required for proper repair of DNA damage
It has been argued that the cycles of oscillation in checkpoint
proteins allow cells to monitor DNA repair and re-activate the
checkpoint response if the damage is still present at the end of each
cycle [24,63]. To assess the applicability of this model to Chk2, we
treated U2OS cells with doxorubicin with or without co-treatment
with the antioxidant N-Acetyl-Cysteine (NAC), which reduces the
amount of DNA damage by scavenging free radicals. As expected,
treatment with the antioxidant reduced caspase activation in
response to doxorubicin. However, if the cells were transfected
with siRNA specific for SMRT, the ability of the antioxidant to
rescue the DNA damage-induced apoptosis was lost (Figure 5A),
suggesting that SMRT is involved in monitoring repair and
shutting down the response if the DNA damage is repaired.
Interestingly, co-treatment with the Wip1 inhibitor partially
restored the ability of the SMRT-deficient cells to block apoptosis
in the presence of NAC (Figure 5A, lane 5), suggesting a role of
Wip1 de-repression in the observed phenomenon.
Finally, we argued that if SMRT is required for properly sensing
and responding to DNA damage, then SMRT knock-down should
affect the ability of the cells to repair DNA damage. As expected,
when SMRT was down-regulated by siRNA, the number of
cH2AX foci, a marker of active repair of DNA double strand
breaks, was doubled (Figure 5B–C).
Discussion
The decision between life and death of a cell is a very important
one, with relevant implications for cancer therapy. Here we
present a role of the transcriptional co-repressor SMRT in
Figure 5. SMRT is required for monitoring the DNA repair process. A) U2OS cells were transfected with scramble siRNA (Ctl) or siRNA against
SMRT and then treated with 5 mM doxorubicin for 6 h, with or without co-treatment with the antioxidant 10 mM N-Acetyl-cysteine (NAC). The data
presented is representative of at least three independent experiments. B–C) U2OS cells were transfected with scramble siRNA or siRNA against SMRT
and treated with 5 mM doxorubicin for 1 h, followed by fixation and immuno-staining with cH2AX antibody. Representative pictures are reported in
B. Five images for each experimental point were taken for each experiment. cH2AX foci from three independent experiments were quantified by
ImageJ software, and the average number of foci per cell was plotted in C. (Student’s T-test; one star: p-value#0.05, two stars: p-value#0.01, three
stars: p-value#0.001). D) Model of modifications in the ATM-Chk2-PPM1D system when SMRT is removed.
doi:10.1371/journal.pone.0059986.g005
SMRT Represses Pro-Apoptotic Genes
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delaying the induction of apoptosis after DNA damage. We
suggest that Checkpoint kinase 2, activated by DNA damage,
induces recruitment of SMRT on the promoters of some pro-
apoptotic genes, thus delaying activation of caspase and allowing
DNA repair (Figure 5D, left panel). When SMRT is removed from
the cells, pro-apoptotic genes are de-repressed and cells activate
the caspase pathway (Figure 5D, right panel). Our data showed
that SMRT is down-regulated both at the RNA level (Figure 1A)
and at the protein level (data not shown) after treatment with
apoptotic doses of CDDP.
The RNA profiling results suggest that SMRT plays a
significant role in gene repression after DNA damage. However,
SMRT actually exhibited an activating action on some CDDP-
regulated genes, possibly due to secondary effects. The genes that
we confirmed by RT-qPCR to be inhibited by SMRT are all
important regulators of apoptosis, belonging to different pathways.
BCL2L11 (or Bim) is a member of the ‘‘BH3-only’’ family of
apoptosis facilitators; members of this family bind and inactivate
pro-survival Bcl2-like proteins, thus allowing permeabilization of
mitochondrial membrane by Bax/Bak channels [64]. SRPK2 is a
protein Serine-Arginine kinase that, after DNA damage, migrates
to the nucleus and induces apoptosis through only partially defined
mechanism [65]. MAX forms a functional dimer with MYC and
binds the promoter of target genes thus inducing cell proliferation
as well as apoptosis [66,67]. Of particular interest, among the pro-
apoptotic genes repressed by SMRT there are some components
or regulators of two major pathways involved in the regulation of
apoptosis: AP1 and NFkB. FOS is a major transcription factor of
the AP1 family [68], and has been associated with induction of
apoptosis after different cellular stresses, including DNA damage
[31,32]. SMAD7 is an inhibitory transcription factor activated by
TGF-b signaling, required for repression of anti-apoptotic NFkB
target genes [69]. The SMRT complex is already known to be
required for gene repression by AP1 [47] and NFkB [46]. In our
experiments, SMRT exerts a basal repressive function on NFkB
genes, as its removal from the cells by siRNA induces up-
regulation of NFkB targets such as PPM1D (Figure 2A) as well as
IL-8 and TNF-a (data not shown). In contrast, active recruitment
of SMRT on the promoter of AP1 targets such as c-FOS occurs
only after DNA damage.
As expected, the SMRT knock-down sensitizes cells to DNA
damaging agents such as CDDP and doxorubicin, increasing
drug-induced caspase activation. An apparently inconsistent
finding is that the Chk2 knock-down does not have the same
effect. Although we were not able to demonstrate direct
phosphorylation of SMRT by Chk2, our data suggest that
phosphorylation of SMRT occurs after treatment with CDDP,
which is reduced, but not entirely abolished, by Chk2 siRNA (data
not shown). Therefore, we are tempted to suggest that SMRT
might be phosphorylated by different kinases after DNA damage,
such as Chk1, p38, and JNK, which can complement the absence
of Chk2.
Of particular interest to us is the SMRT-dependent repression
of the protein phosphatase Wip1 or PPM1D, a down-regulator of
the Chk2 pathway. De-repression of Wip1 by SMRT knock-down
is associated with increased caspase activation. It is tempting to
speculate about potential explanations of these observations. One
hypothesis is that Wip1 de-repression changes the kinetics of Chk2
activation. Chk2 has been reported to be activated in cycles [24].
It has been shown that the frequency of oscillations of a negative
feedback system is dictated by the balance between the activating
stimulus and the negative feedback [60,62]. Therefore, Chk2
oscillations might change in frequency as the system evolves:
initially, when Wip1 levels are low, one observes high-frequency
oscillations (409 period); however, as Wip1 levels increase due to
p53-dependent transcriptional activation (mimicked by SMRT
knock-down), one might expect lower frequency oscillations and,
therefore, more persistent phosphorylation of Chk2 and activation
of caspases. While more detailed kinetic analysis of Chk2
activation would be required to fully characterize the system’s
evolution during time, the idea of frequency modulation as a
strategy to induce different cellular outcomes is a possible
explanation.
Indeed, the idea of alteration in activation dynamics as a
regulatory strategy has been previously proposed. The ATM-
Chk2-p53 pathway has been shown to be activated in cycles after
IR treatment [24]; it has been suggested that the cycles of p53
activation are required to sense the intensity of the DNA damage
[59] and to modulate the response according to the severity of the
damage [70]. Moreover, the kinetics of activation of JNK-1 has
been proposed to dictate the cellular outcome, with transient
activation being pro-inflammatory and pro-survival, while sus-
tained activation inducing cell death [71].
The mechanism of the inhibition of PPM1D gene by SMRT is
not clear. PPM1D has been reported to be regulated by NFkB
[72], which uses SMRT as a co-repressor. However, we were not
able to detect any SMRT protein on the NFkB binding site in the
PPM1D promoter (data not shown). It is possible that the effect on
Wip1 is indirect, mediated by increased autocrine secretion of
TNF-a by the SMRT knock-down cells. Indeed, treatment of the
cells with exogenous TNF-a has an effect on caspase activation
similar to that of siRNA for SMRT: increased doxorubicin-induced
apoptosis, which can be rescued by siRNA for Wip1 (data not
shown).
Finally, Wip1 regulates many different kinases [55] and,
therefore, its regulation has most likely wider consequences than
only those dependent on Chk2 oscillation. We speculate that
oscillatory behavior occurs simultaneously in many different
systems and for many different regulatory proteins, wherever a
negative feedback loop is present, and the final ‘‘decision’’ on cell
fate depends on the balance between the signals sent by each of the
regulatory checkpoint proteins.
Materials and Methods
Antibodies, siRNAs, chemicals and cell lines
Antibodies specific for NCoR were generated in our laboratory
as previously described (50). All the other antibodies were
commercial: Flag (SIGMA), cleaved PARP (human-specific),
cleaved caspases 3 (Asp175) and phospho-Chk2 (T68) (Cell
Signaling Technology), SMRT (Abcam for Western blot, Affinity
Bioreagents for chromatin immunoprecipitation), GAPDH (Santa
Cruz Biotechnology), b-tubulin (SIGMA), cH2AX (Upstate,
mouse monoclonal). The following chemicals were used: TNF-a,
PPM1D inhibitor (Calbiochem), TPA, 9cis-RA, cisplatin, doxo-
rubicin, cycloheximide and N-acetyl-cysteine (SIGMA).
SiRNAs specific for Chk2, NCoR, SMRT and PPM1D were
purchased from Invitrogen, and a mix of three independent
siRNAs was used for each gene.
All cell lines (U2OS, HeLa, 293) were purchased from ATCC.
Cell culture
All cells were grown in Dulbecco Modified Eagle Medium
(GIBCO) with low glucose, supplemented with 10% FBS and
50 mg/ml Gentamycin. For transfection, Lipofectamine 2000-
based liposomes were incubated in serum-free medium (5 ml/
plate) and Optimem medium (3 ml/plate) for 6 hours, followed by
incubation in complete medium for 2 days before the appropriate
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treatments. Cells were incubated for 2 days in serum-free DMEM
medium before treatments with 9cisRA, TNF-a or TPA.
Reverse Transcription-qPCR
Total RNA was extracted with RNEasy kit (QIAGEN)
according to the manufacturer’s recommendations, and 1 mg of
RNA was used for RT reaction by SuperScript III Reverse
Transcriptase kit (Invitrogen); cDNA samples were diluted 1:20 for
test genes and 1:200,000 for the reference gene (18S), and 4 ml per
reaction were used for qPCR, using Brilliant III SYBR Green
master mix (Agilent). Results from three technical replicates were
analyzed by the DDCt method, using 18S as a normalizer. Briefly,
statistical significance was calculated by normalizing the values of
three independent biological replicates for the respective 18S
values, eliminating the outliers and averaging the DCts; the p-
value was calculated by Student’s T-test.
Chromatin Immunoprecipitation
After the appropriate transfections and treatments, HEK293
cells were fixed by incubation for 109 with 2% formaldehyde and
then in 0.125 M Glycine for 159. Cells were harvested in PBS, the
pellet was washed sequentially in ChIP Buffer I (0.25% Triton X-
100, 10 mM EDTA, 0.5 mM EGTA, 10 mM HEPES pH 6.5)
and ChIP Buffer II (200 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA, 10 mM HEPES pH6.5) and then incubated for 1 h in
Lysis Buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.1,
1X Complete protease inhibitor mix [Roche]). Chromatin was
sonicated by BioRuptor (Diagenode, 8 pulses, 59 each on High
setting, 50% time pulses), diluted 1/10 in Dilution buffer (1%
Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl
pH 8.0, protease inhibitor mix) and immunoprecipitated with 5 ml
NCoR or SMRT antibodies over night, followed by incubation for
2 h with protein A sepharose (Invitrogen, 50 ml/sample of 50%
slurry) or protein A Dynabeads (Invitrogen, 15 ml/sample of
30 mg/ml mix). The immunoprecipitate was washed sequentially
in TSE-I (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM
Tris-HCl pH8.0), TSE-II (0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 20 mM Tris-HCl pH 8.0, 500 mM NaCl), Buffer III
(0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA,
10 mM Tris-HCl pH 8.0) and twice in TE Buffer, then
resuspended in Elution Buffer (1% SDS, 0.1 M NaHCO3) and
de-crosslinked at 65uC for 6 hrs. DNA was extracted through
QIAquick Spin columns (QIAGEN), diluted 1:4 and 4 ml were
used for qPCR, using technical triplicates. Percentage of the input
was calculated by performing four serial 1/5 dilutions of 1% input.
All qPCR reactions were performed as described for RT-qPCR.
The results shown derive from averaging three independent
experiments; the statistical significance was calculated by Student’s
T-test.
Microarrays
U2OS cells were transfected with siRNAs for NCoR or SMRT,
incubated in complete medium for 2 days, and then treated with
100 mM CDDP for 6 hrs, followed by RNA extraction, labeling
with Illumina TotalPrep RNA Amplification Kit (Ambion) and
hybridization on Illumina Expression Beadchips (HumanRef 8.0),
following the manufacturer’s recommendations. Data was ana-
lyzed as described in Methods S1. The data was uploaded on the
GEO database (ID number: GSE34226).
Cell extracts and fractionation
For whole cell extracts, Cells were washed in cold PBS,
harvested and resuspended in IPH buffer (50 mM Tris-HCl
pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1 mM
PMSF, 50 mM NaF, 2 mM Na2VO3, 1X Complete protease
inhibitor mix [Roche] and 1 mM glycerol phosphate), incubated
for 209 on ice and subsequently centrifuged for 109 at 13,000 rpm.
The supernatant (whole cell extract was used for Western blot
analysis.
Immunofluorescence
U2OS cells were plated at 80% confluence in 8-well plates,
transfected as indicated with Lipofectamine 2000 (Invitrogen) and
then treated with 5 mM doxorubicin for 1 h. Cells were fixed in
2% paraformaldehyde for 109 at room temperature and then
washed in PBS 4 times (209 each), followed by permeabilization in
0.1% NP-40 in PBS (309 at room temperature) and incubation in
PGBA-Super blocking solution (0.1% gelatin, 10% BSA, 0.01%
sodium azide, 1% normal goat serum in PBS) for 309 at room
temperature. Primary antibody anti-cH2AX was diluted 1:200 in
PGBA solution (0.1% gelatin, 1% BSA, 0.01% sodium azide in
PBS) and added to the cells over-night. Cells were washed 4 times
in PBS and then incubated for 1 h with secondary antibody anti-
mouse (1:300 in PGBA) conjugated with Alexa-488 (Invitrogen).
Cells were washed 3 times in PBS and then analyzed at the
fluorescence microscope at 20X magnification. Five pictures were
taken for each experimental point. cH2AX foci were counted with
ImageJ, using the FociPicker3D application, followed by counting
the number of cells for each picture with the ‘Analyze Particles’
function, and the number was used to calculate the average
number of foci per cell. Data from three independent experiments
were used to calculate statistical significance, with Student’s T-test.
Supporting Information
Figure S1 Purification of proteins interacting with the
FHA of Chk2. A) A PATH-tagged FHA domain of Chk2 was
purified from bacteria and incubated with cellular extracts from
HeLa cells. As a control, a mutant lacking the ability to bind target
phosphopeptides was used. Purified proteins were run on
polyacrylamide gels and visualized with silver stain. B) Proteins
identified to specifically interact with the FHA domain of CHK2.
C) U2OS cells were transfected with Flag-tagged Chk1 or Chk2
expression vectors, and protein extracts were immunoprecipitated
with anti-Flag antibody, followed by SDS-PAGE and Western Blot
analysis. D) U2OS cells were transfected with the indicated
reporters with or without siRNA against Chk2, incubated for 2
days in serum-free medium and then treated with 10 ng/ml TPA,
20 ng/ml TNF-a or 561028 M 9cisRA, as indicated. Statistical
significance was calculated on the ratio between luciferase
luminescence and Renilla luciferase from three independent
experiments, each one including four technical replicates, by
Student’s T-test. (One star: p-value#0.05, two stars: p-val-
ue#0.01, three stars: p-value#0.001).
(TIF)
Figure S2 Time-course of cisplatin (CDDP) treatment.
U2OS cells were treated with 100 mM CDDP for the indicated
time points and the whole cell extracts were used for Western blot
with specific antibodies against phospho-Chk2 (T68), cleaved
PARP (Asp214), or b-tubulin.
(TIF)
Table S1 Genes regulated by cisplatin. The table reports
the total number of genes resulting regulated by CDDP in the
microarrays experiment, ranked by significance as described in
Methods S1.
(XLS)
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Table S2 Genes whose regulation by cisplatin is
affected by NCoR. The table reports the total list of genes
whose regulation by CDDP in the microarray experiments was
different in the cells transfected with NCoR siRNA compared to the
cells transfected with scramble control siRNA.
(XLS)
Table S3 Genes whose regulation by cisplatin is
affected by SMRT. The table reports the total list of genes
whose regulation by CDDP in the microarray experiments was
different in the cells transfected with SMRT siRNA compared to
the cells transfected with scramble control siRNA.
(XLS)
Methods S1 Methods for the data included in Support-
ing Figures and detailed descriptions of microarray data
analysis, plasmids and qPCR primers are included.
(DOC)
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